Vyxeos

Phase 2Small molecule

CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Vyxeos is one of 113 small molecule programs targeting Leukemia, Myeloid, Acute. It is currently in Phase 2.

Indications

Total Trials

Active Trials

112

Competitors

Pipeline

Status by Indication[3][1]

Indication

Leukemia, Myeloid, AcuteActive, not recruiting

Relapsed or RefractoryRecruiting

Newly DiagnosedRecruiting

LipUnknown status

Acute LeukemiaRecruiting

Leukemia, Myeloid, AcutePhase 2

Active, not recruiting

Relapsed or RefractoryPhase 1

Recruiting

Newly DiagnosedPhase 1

Recruiting

LipPreclinical

Unknown status

Acute LeukemiaPhase 1

Recruiting

Competition

Competitive Landscape

83 competitors in Newly Diagnosed

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 3

17 2

Cytosar

Teva

Phase 3

15 3

Rituxan

Roche

Phase 3

12 4

Oncovin

Eli Lilly

Phase 3

7 5

Adriamycin

Pfizer

Phase 3

6 6

Decadron

AAspen Global Incorporated

Phase 3

17 7

Darzalex

Johnson & Johnson

Phase 3

4 8

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

15 9

Cytoxan

BBaxter Healthcare Corporation

Vanflyta

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Relapsed or Refractory

NCT05024552

Q2 2027

Phase 1Recruiting

Newly Diagnosed

NCT05558124

Q1 2028

Phase 1Recruiting

Acute Leukemia

NCT03826992

Q3 2028

Phase 2Active, not recruiting

Leukemia, Myeloid, Acute

NCT05599360

Clinical

Trials by Indication[1]

Acute Leukemia1 trial

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Recruiting·—·Phase 1·NCT03826992·21 enrolled

Acute Myeloid Leukemia1 trial

Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.

Terminated·UUniversity of California, San Diego·Phase 2·NCT04425655·2 enrolled

Relapsed or Refractory1 trial

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT05024552·22 enrolled

Treatment1 trial

A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

Unknown status·UUniversity of Birmingham·Phase 2/3·NCT04217278·333 enrolled

Newly Diagnosed1 trial

CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT05558124·18 enrolled

2 more indications

Lip1 trial

A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection

Unknown status·CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.·N/A·NCT05801835·36 enrolled

Leukemia, Myeloid, Acute1 trial

Vyxeos for Induction of Newly Diagnosed Low- or Intermediate-risk AML Patients, Age 18-70. A Pilot Study

Active, not recruiting·SShaare Zedek Medical Center·Phase 2·NCT05599360·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Vyxeos. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vyxeos compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vyxeos. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Vyxeos

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q1 2028

Q3 2028

Trials by Indication[1]

Acute Leukemia1 trial

Acute Myeloid Leukemia1 trial

Relapsed or Refractory1 trial

Treatment1 trial

Newly Diagnosed1 trial

Lip1 trial

Leukemia, Myeloid, Acute1 trial

References

Drug Info

Quick Facts

Related News